导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -2.68% | 2984/4773 |
| 近一周 | -2.05% | 1126/5462 |
| 近一月 | -3.50% | 1792/5421 |
| 近一季 | -2.72% | 1292/5209 |
| 近半年 | -4.72% | 2594/4920 |
| 近一年 | -1.79% | 2923/4366 |
| 近两年 | 33.31% | 2150/2954 |
| 近三年 | 18.71% | 1521/2253 |
| 成立以来 | 206.76% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.67% 2856/4961 |
5.18% 2888/5312 |
- - |
- - |
| 2025 | 12.01% 2712/4813 |
-1.98% 2827/3635 |
0.97% 2515/4076 |
14.13% 2944/4524 |
-0.84% 2676/4813 |
| 2024 | 15.70% 898/3463 |
3.79% 513/2808 |
-0.53% 783/3014 |
15.75% 1634/3129 |
-3.17% 2280/3463 |
| 2023 | -3.62% 645/2656 |
6.79% 644/2280 |
-2.20% 566/2385 |
-2.80% 752/2515 |
-5.06% 1244/2655 |
| 2022 | -17.47% 595/2207 |
-13.36% 744/1919 |
6.03% 785/2016 |
-12.93% 809/2113 |
3.18% 755/2208 |
| 2021 | 13.23% 361/1822 |
3.22% 192/1255 |
4.96% 835/1330 |
2.33% 437/1466 |
2.13% 690/1822 |
| 2020 | 36.01% 406/1250 |
-7.87% 576/1028 |
8.67% 818/1067 |
18.60% 79/1164 |
14.53% 268/1184 |
| 2019 | 31.07% 477/1092 |
24.17% 525/754 |
-1.89% 333/804 |
1.97% 338/850 |
5.51% 710/918 |
| 2018 | -16.95% 119/834 |
- - |
- - |
- - |
-10.05% 174/691 |
| 2017 | 20.77% 176/714 |
- - |
- - |
- - |
- - |
| 2016 | -8.52% 247/605 |
- - |
- - |
- - |
- - |
| 2015 | 11.72% 153/575 |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 财通中证ESG100指数增强A VS. 长安沪深300非周期A(740101) |